Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery
NCT ID: NCT00125320
Last Updated: 2007-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
190 participants
INTERVENTIONAL
2004-06-30
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSD1235
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Advanz Pharma
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fort Lauderdale, Florida, United States
Atlanta, Georgia, United States
Buenos Aires, , Argentina
La Plata, , Argentina
Calgary, Alberta, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Aalborg, DK, Denmark
Hellerup, DK, Denmark
Odense C, DK, Denmark
Bangalore, , India
Chennai, , India
Hyderabaad, , India
Kerala, , India
Mohali, , India
Mumbai, , India
New Delhi, , India
Katowice, , Poland
Krakow, , Poland
Lodz, , Poland
Warsaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9. doi: 10.1161/CIRCEP.109.870204.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1235-0104
Identifier Type: -
Identifier Source: org_study_id